A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation
ConclusionNeratinib and trametinib combination was toxic and had limited clinical efficacy. This may be due to suboptimal drug dosing given drug –drug interactions.Trial registration ID: NCT03065387.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Drugs & Pharmacology | Genetics | HER2 | Toxicology